Once the first year has been completed, members often continue with individual support and follow-up through Itrim's second year Balance Program (see below).

The weight loss program comprises three phases: the Weight Loss Phase (first 12 weeks), the Improvement Phase (from week 13 to the end of the first year), and the Balance Phase (year 2 onwards, for as long as the member wishes).
Throughout the program members exercise 30 minutes at the center 2-3 times each week (combined aerobic and strength training in a circuit), and use pedometers and fitness tracking devices to monitor and increase their daily exercise.
Weight Loss Phase
Background to Excess Weight and Weight Loss
INTRODUCTION
Because most US and European adults are overweight or obese (1, 2), health services are struggling to cope with the large number of individuals in need of weight loss. Bariatric surgery induces large weight losses and reduces type 2 diabetes and mortality (3) (4) (5) (6) but is generally restricted to severely obese individuals with comorbidity, whereas antiobesity drugs are struggling to gain Food and Drug Administration approval (7) . Many overweight and obese individuals, therefore, find their options limited to commercial weight-loss programs, most of which have not been scientifically evaluated (8, 9) .
Weight Watchers and Jenny Craig are 2 commercial weightloss operators whose programs have been evaluated in long-term ($1 y) randomized controlled trials (10, 11) . A recent randomized trial found that a commercial weight-loss program (Weight Watchers) was twice as effective as standard care at reducing body weight after 2 y (24.0 compared with 21.8 kg, intention-to-treat analysis with baseline carried forward) (12) .
Research on commercial weight loss is still scarce, however, and there is a need to quantify the effectiveness of commercial weightloss diets, especially in real-life settings. The aim was to evaluate weight loss and the dropout rate after 1 y of a commercial weightloss program in Sweden, where weight loss was induced with a 500-kcal very-low-calorie diet (VLCD) 4 , a 1200-1500-kcal lowcalorie diet (LCD), or a 1500-1800-kcal restricted normal-food diet followed by a diet and exercise maintenance program.
SUBJECTS AND METHODS
Recruitment
Participants were consecutively enrolled customers (n = 9037) from the commercial weight-loss company Itrim in Sweden from 1 January 2006 to 31 May 2009 (see Figure S1 under "Supplemental data" in the online issue). Data were collected from 28 centers across Sweden. All customers were enrolled in the Itrim weight-loss program. The regional ethics review board in Stockholm approved the study (registration numbers 2010/ 151-31/5 and 2010/1059-31/1).
Weight-loss programs
The 1-y weight-loss program consisted of an initial 3-mo weight-loss phase followed by a 9-mo weight-maintenance phase. At the start of the weight-loss phase, participants and their designated health coaches discussed and decided on an appropriate weight-loss diet that was largely based on baseline BMI, desired weight loss, and personal preference: 1) VLCD: consisted of a liquid-based formula diet of 500 kcal/d for 6 to 10 wk (Itrim; 125 kcal/sachet, 4 sachets/d, each sachet contained 13 g protein, 15 g carbohydrates, 2 g fat, and 3 g fiber; approved as the sole-source VLCD by the Swedish National Food Agency) followed by a 2-wk gradual introduction of normal food. Early introduction of normal food (6 as opposed to the full 10 wk) occurred when the participant was either satisfied with the achieved weight loss or had reached a normal-weight BMI (in kg/m 2 ) of #25.
2) LCD: consisted of 2 calorie-restricted normal-food meals and 2 formula-diet meal-replacement sachets providing a total caloric intake of w1200-1500 kcal/d depending on body size and exercise levels. 3) Restricted normal-food diet: consisted mainly of food with high protein, low-glycemic-index carbohydrates, low fat intake, low energy density, and a high fiber content, providing a caloric intake of w1500-1800 kcal/d depending on body size and exercise levels.
After the weight-loss phase, all 3 groups entered the same 9-mo weight-maintenance program, which included an exercise program (circuit training, with a mix of aerobic and strengthtraining workout stations, at the center 2-3 times/wk for 30 to 45 min; physically active transport to and from work; and use of a Yamax SW-200 pedometer to encourage walking), dietary advice, and behavioral changes. Dietary advice included the use of restricted portions sizes and consumption of a diet rich in protein, with a low glycemic index, and with a low overall energy density (eg, consumption of vegetables and water as opposed to caloric beverages).
TABLE 1
Baseline characteristics (n = 9037) of participants in a commercial weight-loss program including a VLCD (500 kcal/d), an LCD (1200-1500 kcal/d), or a restricted normal-food diet (1500-1800 kcal/d)
Restricted normal-food diet (n = 676) P 3 VLCD compared with LCD. 4 VLCD compared with restricted normal-food diet. 5 LCD compared with restricted normal-food diet. 6 Waist circumference $102 cm for men, $88 cm for women. 7 Drug use was assessed during the period 6 mo before baseline through register linkage with the Prescribed Drug Register, whereas comorbidity data (except for diabetes) were retrieved from the National Patient Register during the past 5 y. Because diabetes is, to a large extent, treated in primary care, it was defined as use of either insulin or oral antidiabetics. Group differences were analyzed by using ANOVA with a Scheffe post hoc test.
Behavioral changes were facilitated by using a structured support program, which included weekly 1-h group sessions during the weight-loss phase and every 4 wk during the weightmaintenance phase (20 in total). Each session was supervised by a company-trained health coach, who provided encouragement to participants throughout the program. Each group session covered a specific topic, such as health benefits of weight loss, healthy eating strategies, finding realistic eating and exercise routines, and stress management. There were also 30-min face-to-face counseling sessions at baseline and 3, 6, and 12 mo. Self-monitoring was facilitated through diaries, including diet and exercise plans, and graphs for plotting weight, waist circumference, planned and completed circuit training sessions, and steps per day.
Specific restrictions with use of a VLCD
Although participants were free to choose their method of weight loss, the company used criteria for use of VLCDs, consistent with the VLCD recommendations of the European Union Scientific Cooperation Task Report (13) . First, individuals were required to have a BMI $30 or a BMI $27 with elevated waist circumference ($102 cm for men and $88 cm for women). In addition, unless they had signed approval from their physician, individuals with any of the following conditions were barred from following a VLCD: insulin-treated diabetes, gallstones, gout, cancer during the past 2 y, cardiovascular disease (CVD) during the past 3 mo, pregnancy, breastfeeding, catabolic disease, kidney disease, anorexia nervosa, or bulimia.
Cost
The cost for attending the 1-y weight-loss program (including the exercise program) was w9000 Swedish krona (wUS$1300, €1000), excluding the liquid diets. At the start, all participants either paid for the whole 12-mo period or committed to paying the whole amount in monthly installments. All participants paid their own fees.
Observational data on weight loss and dropout
The primary outcome variable was weight loss after 1 y. Data on body weight and waist circumference were collected at baseline and 3, 6, and 12 mo. Body weight was measured with the TBF-300 
TABLE 3
Adjusted between-group differences in absolute and relative body weight and waist circumference in participants after 1 y in a commercial weight-loss program (n = 9037) including a VLCD (500 kcal/d), an LCD (1200-1500 kcal/d), or a restricted normal-food diet (1500-1800 kcal/d) bioelectrical impedance scales (Tanita Corporation). Waist circumference was measured at the point midway between the iliac crest and the lower rib (exhaled). Height was measured with a wallmounted stadiometer. Dropout was defined as missing data on body weight during 10-14 mo from baseline, including body weight measured at group sessions, and the 1-y follow-up.
Linkage with data from National Health Care Registers
Data on history of comorbidities during the past 5 y were collected from the Swedish National Patient Register, which includes virtually all inpatient and nonprimary outpatient care visits (14) . Data on hospital visits for malignancies (International Classification of Disease, Tenth Revision code C00-C97) and CVD (code I00-I99) were also collected. Data on diabetes treated with insulin [Anatomic Therapeutic Chemical classification system (ATC) code A10A] or oral antidiabetic drugs (ATC A10B) were collected from the Prescribed Drug Register. Drug dispensation data were retrieved from the Prescribed Drug Register during the 6 mo preceding the start of the program. We also collected data on dispensations of antihypertensive drugs (ATC C02, C03, C07, C08, and C09), lipid-lowering agents (ATC C10AA, C10AB, C10AC, C10AD, C10B, and C10AX), antipsychotics (N05A), antidepressants (ATC N06A), and the antiobesity drugs orlistat (A08AB01) and sibutramine (A08AA10). Finally, we collected data from the Causes of Death Register (for a data linkage outline, see Online Supplementary Material under "Supplemental data" in the online issue).
Statistical analyses
Weight loss was primarily analyzed with an intention-to-treat analysis by using baseline observation carried forward when follow-up data were missing. In sensitivity analyses, we also used last observation carried forward, multiple imputation (age, sex, and baseline value were used to predict missing values at 1 y), and FIGURE 1. Absolute values for and changes in BMI, body weight, and waist circumference during a 12-mo commercial weight-loss program including a VLCD (500 kcal/d), an LCD (1200-1500 kcal/d), or a restricted normal-food diet (1500-1800 kcal/d). ANCOVA was conducted, and the data are estimated marginal means adjusted for age, sex, center, calendar year, history of cardiovascular disease and cancer, and dispensation of drugs for obesity, diabetes, hypertension, dyslipidemia, depression, or psychosis. Error bars represent 95% CIs. ITT: BOCF, intention to treat with use of baseline observation carried forward; ITT: LOCF, intention to treat with use of last observation carried forward; ITT: MI, intention to treat with use of multiple imputation; LCD, lowcalorie diet; VLCD, very-low-calorie diet.
a completers-only analysis to see whether our findings were affected by the choice of data-imputation method.
When quantifying the within-group effects of the 3 weightloss diets, we used a paired sample's t test. Between-group comparisons were performed by using ANCOVA with adjustment for age, sex, baseline body weight, center, calendar year, drug dispensations, and comorbidities. Multiple linear regression was used to study predictors of weight loss, and we used multivariable logistic regression to identify predictors of dropout.
When analyzing dropout within groups, we excluded data from the restricted normal-food group because of insufficient power. Because we wanted to study the potential influence of initial weight loss on dropout, we excluded participants who dropped out before the 3-mo follow-up. A 2-sided P value ,0.05 was considered statistically significant. All data were analyzed with SPSS version 20 and SAS statistical software (version 9.3; SAS Institute Inc).
RESULTS
The mean age of the participants was 48 6 12 y (range: 18-81 y), BMI was 32 6 5 (range: 18-68), and waist circumference was 105 6 13 cm (72-164); 83% of the participants were women, 4% were normal weight, 38% were overweight, 37% were class I obese, 15% were class II obese, and 6% were class III obese ( Table 1) .
During the 5 y preceding baseline, 8% of all participants had hospital visits listing diagnoses for CVD and 2% with cancer. During the 6-mo period preceding baseline, 18% were dispensed antihypertensives, 12% antidepressants, 7% lipidlowering drugs, 2% oral antidiabetics, 1% insulin, and 1% antipsychotics.
Weight loss after 1 y: intention-to-treat analysis
The unadjusted mean (6SD) weight change in the 3 weightloss groups combined was 28.6 6 8.0 kg (29.5% of baseline body weight). Within-group weight changes were 211.4 6 9.1 kg with the VLCD, 26.8 6 6.4 kg with the LCD, and 25.1 6 5.9 kg with the restricted normal-food diet (P , 0.001 for all within-group changes; Tables 2 and 3) . BMI, percentage weight loss, and waist circumference were likewise reduced in a doseresponse relation according to caloric intake ( Figure 1) . A higher proportion of participants in the VLCD group also lost $15% body weight, and there were fewer participants who lost ,5% of body weight (Figure 2) .
After adjustment for covariates (baseline body weight, age, sex, calendar year, center, comorbidities, and drug dispensations), the VLCD group lost 2.8 kg (95% CI: 2.5, 3.2) more than did the LCD group and 3.8 kg (95% CI: 3.2, 4.5) more than did the restricted normal-food diet. The LCD group lost 1.0 kg (95% CI: 0.4, 1.6) more than did the restricted normal-food diet group.
Weight loss after 1 y: completers-only analysis
In the completers-only analysis, the unadjusted mean (6SD) weight change for all 3 weight-loss groups was 210.9 6 7.5 kg, equivalent to 12.0% of baseline body weight. Within-group, unadjusted weight changes were 213.9 6 8.1 kg for the VLCD group, 28.8 6 5.9 kg for the LCD group, and 26.9 6 5.9 kg for the restricted normal-food group.
By using linear regression we found that higher baseline body weight (Figure 3) , greater initial weight loss, and female sex were associated with increased weight loss after 1 y across all weight-loss groups (P , 0.01-0.001; see Table S1 under "Supplemental data" in the online issue). A history of treatment with the previously available antiobesity drug sibutramine predicted a smaller weight loss after 1 y in the VLCD and LCD groups (P = 0.026 and P = 0.008, respectively).
Dropout after 1 y
Crude dropout rates were 18% in the VLCD group, 23% in the LCD group, and 26% in the restricted normal-food group. In multivariable analysis, with adjustment for age, sex, baseline BMI, center, calendar year, and comorbidities and drug dispensations, and with the use of the VLCD group as reference, dropout was significantly higher in the LCD group (OR: 1.43; 95% CI: 1.27, 1.62; P , 0.001) and restricted normal-food group (OR: 1.66; 95% CI: 1.37, 2.01; P , 0.001).
Within the VLCD group, younger age (,40 y) and low initial weight loss (,5%) after 3 mo were associated with an increased dropout rate ( Table 4) . Drug dispensations for depression and psychosis were also associated with an increased risk of dropout. Within the LCD group, predictors of dropout were younger age (,40 y), a low BMI at baseline (,30), and a low initial weight loss (,5% of baseline body weight). Sex, history of treatment of CVD or cancer, or drug dispensation for hypertension, dyslipidemia, or diabetes were not associated with dropout.
Sensitivity analysis
To minimize the influence of choice of method for handling missing data, we carried out sensitivity analysis using last observation carried forward, a completers-only analysis, and multiple imputation. None of the 3 alternative data-imputation methods produced results that differed materially from the main analysis (Figure 1 ).
DISCUSSION
Main findings
Weight loss was largest in the 500-kcal VLCD group, followed by the 1200-1500-kcal LCD group, and finally the 1500-1800 restricted normal-food group, which demonstrated a linear, dose-response relation between energy intake and reduced body weight during commercial weight loss. The differences in effectiveness between weight-loss methods were similar when we analyzed waist circumference and percentage body weight as outcome variables. Moreover, the effects of weight-loss method were independent of covariate adjustment and the method for handling missing data.
Baseline body weight and rapid initial weight loss were also independently associated with greater weight loss after 12 mo, whereas treatment of CVD, cancer, hypertension, dyslipidemia, ) and a VLCD (500 kcal/d; n = 3773), an LCD (1200-1500 kcal/d; n = 4588), and a restricted normal-food diet (1500-1800 kcal/d; n = 676) at predicting percentage weight loss after 1 y in a commercial weight-loss program. ANCOVA was conducted with adjustment for age, sex, center, calendar year, history of cardiovascular disease and cancer, and dispensation of drugs for obesity, diabetes, hypertension, dyslipidemia, depression, and psychosis. Data are estimated marginal means. LCD, low-calorie diet; VLCD, very-low-calorie diet. depression, diabetes, or psychosis did not influence weight loss. Dropout was lowest in the VLCD group, followed by the LCD group, and finally the restricted normal-food group. Younger age and low BMI (the latter for the LCD group only) were associated with increased dropout. Previous treatment of depression and psychosis was also associated with increased dropout in the VLCD group.
Potential mechanisms for the observed effects
The finding that weight loss was determined in a linear doseresponse relation according to energy intake suggests that the laws of thermodynamics were the major determinants of weight loss. Moreover, there was no difference in exercise programs between weight-loss groups [Itrim also operates an exerciseonly program, with a mean (6SD) weight and waist reduction of 1.6 6 4.3 kg and 2.4 6 5.2 cm after 1 y; completers-only analysis, n = 570, data not shown].
Greater initial weight loss during the first 3 mo was also associated with improved 1-y weight loss and reduced the dropout rate, indicating that a good start promotes long-term compliance, possibly through increased motivation (15) . The markedly increased risk of dropout associated with younger age needs to be studied further.
Comparisons with other commercial weight-loss programs
Weight Watchers and Jenny Craig have both evaluated their programs in randomized trials. Weight Watchers promotes a balanced, hypoenergetic, normal-food diet according to healthy-eating principles (12) . In an intention-to-treat analysis with baseline carried forward, mean weight loss after 1 y was 4.1 kg (within-group analysis) and the dropout rate was 42% (12) .
Jenny Craig initially uses prepackaged meals with a low fat and low energy content, typically 1200-2000 kcal/d, and then gradually reintroduces a greater proportion of normal food. In an intention-to-treat analysis with baseline carried forward, mean weight loss after 1 y was 6.6 kg (within group), and the dropout rate was 9% (16) . In the completers-only analysis, weight loss was 7.3 kg-almost identical to the 7.0 kg lost by completers in 1 Drug use was assessed during the period 6 mo before baseline through register linkage with the Prescribed Drug Register, whereas comorbidity data (except for diabetes) were retrieved from the National Patient Register during the past 5 y. Because diabetes is, to a large extent, treated in primary care, it was defined as use of either insulin or oral antidiabetics.
We were not able to analyze the restricted normal-food diet group because of insufficient power and likewise for the antiobesity drug orlistat (only sibutramine was analyzed). There were 3466 participants with complete data on dropout predictors in the VLCD group (91.9%), of whom 532 dropped out, and 4163 in the LCD group (90.7%), of whom 818 dropped out. ORs were quantified by using multivariable logistic regression. CVD, cardiovascular disease; LCD, lowcalorie diet; VLCD, very-low-calorie diet.
the restricted normal-food group in the current study. The greater weight losses seen in the current study suggest that liquid low-calorie formula diets that promote rapid initial weight loss can improve both weight loss and the dropout rate in commercial weight-loss programs.
However, differences in study protocols, participants, and payment complicate direct comparisons of the effectiveness of the Itrim program with Weight Watchers, Jenny Craig, and other commercial weight-loss programs. Observational studies, such as the current analysis, are likely to benefit from highly motivated, self-selected, and self-paying participants. Similarly, randomized trials may benefit from having a controlled environment and added visits with study personnel, doctors, and nurses.
Concerns with use of a VLCD
VLCDs have been associated with adverse events, such as gallstone formation and sudden death (17) (18) (19) , which have contributed to stricter rules in the United States (where VLCD programs must be managed by a physician) than in Europe (8) . Rapid weight loss, whether by VLCD or bariatric surgery, increases the risk of developing gallstones, and clinical recommendations advise physicians to inform patients about this risk (13, 17, 20) . Gallstone formation has mainly been associated with VLCDs containing low amounts of fat (w1 g/d) (21) (22) (23) (24) (25) , and a higher fat content (12-30 g/d) seems to reduce gallstone formation (26) (27) (28) (29) .
Another concern with VLCDs is weight regain. Although initial weight loss predicted lower body weight at follow-up in the current study and in others (30), rapid weight loss was also associated with greater regain during the weight-loss maintenance phase in all 3 weight-loss groups (see Figure S2 under "Supplemental data" in the online issue). Responsible use of VLCDs requires, at a minumum, a weight-loss maintenance program, transparency about the substantial efforts required to maintain weight loss (9, (31) (32) (33) (34) and risk of regain, and exclusion of nonobese individuals.
Strengths and limitations of the study First, it was not possible to randomly assign participants to different weight-loss methods, meaning that between-group comparisons are affected by selection bias and baseline differences. We tried to minimize confounding from baseline differences by using percentage weight loss in addition to absolute weight loss, and we performed a BMI-stratified analysis ( Figure  3) . We also adjusted for baseline body weight in between-group analyses. Our study was aided by a large sample size and the use of 3 different energy-intake methods. The data were furthermore collected in consecutively enrolled participants in a real-life setting, as opposed to data collected in a controlled research setting, where more strict inclusion criteria can limit external validity. We also supplemented the observational data on effectiveness with data from national health registers, which allowed us to describe the medical history of our participants and the influence of such data on effectiveness.
Conclusion
Both weight-loss and dropout rates were more favorable for the 500-kcal/d VLCD group than for the 1200-1500-kcal/d LCD group and the 1500-1800-kcal/d restricted normal-food group, which suggests an approximately linear dose-response relation between initial caloric intake and long-term effectiveness during commercial weight loss.
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INTRODUCTION
Bariatric surgery is currently the most effective treatment for obesity, 1 but all obese patients cannot undergo surgery because of guidelines, contraindications, capacity constraints and patient preferences. With the limited capacity of hospital-based obesity treatment, commercial weight loss programs including intensive treatment such as very-low-calorie diets (VLCDs; defined as o800 kcal per day) 2 are used by millions each year.
2-4
The effects of commercial weight loss programs have shown to equal or even outweigh primary-care programs, 5 with initial rapid weight loss using VLCD compared with low-calorie diet program (LCD; 1200-1500 kcal per day) inducing greater 1-year weight losses and lower dropout rates. 6 However, the safety of commercial programs has rarely been studied, and using VLCD in commercial weight loss programs is a particular concern given the risk of adverse events as well as weight regain. [7] [8] [9] A commonly described adverse event after rapid weight loss (including VLCD) is gallstones. Previous studies of VLCD-induced rapid weight loss have generally been small, of short duration, lacked control groups and used formulations with lower amounts of fat compared with the formulations used today. [10] [11] [12] [13] [14] These previous studies have all identified gallstone formation with ultrasonography after VLCD use. However, the majority of the gallstones found in these studies were asymptomatic, and few led to symptoms. The risk of symptomatic gallstones requiring hospital care and/or cholecystectomy, potentially serious adverse events after VLCD use, has not been studied. Further, to the best of our knowledge, there are no large-scale studies on the safety of commercial weight loss programs. The aim of this matched cohort study was to investigate in a real-life setting the risk of symptomatic gallstones leading to hospitalization or cholecystectomy after using VLCD (500 kcal per day for 6-10 weeks) compared with participants on LCD (1200-1500 kcal per day for up to 3 months) during a 1-year commercial weight loss program.
METHODS
This matched cohort study was conducted in the commercial weight loss setting in Sweden. Participant data were retrieved from the database used by the commercial company to track customer progress and compliance. These data were linked to the National Patient Register, 15 containing inpatient and nonprimary outpatient care, for outcome ascertainment, and to the Causes of Death Register for follow-up of vital status (Figure 1) . The regional Ethics Committee in Stockholm, Sweden, approved the study.
Participants
Included participants were consecutively enrolled adult customers (age X18years; n ¼ 8361) from the commercial weight loss company Itrim in Sweden (www.itrim.se) from 1 January 2006 to 31 May 2009. Data were collected from 28 centers across Sweden, as described elsewhere. 6 
Interventions
The weight loss program was of 1-year duration and comprised an initial 3-month weight loss phase, followed by a 9-month weight maintenance phase. At enrollment, participants selected one of three programs (VLCD, LCD or normal food, as described elsewhere 6 ). In this study, we report data from the VLCD and LCD groups, as these are the two programs including liquid formula diets. Although all participants were paying customers and were free to choose weight loss method, the company used criteria for VLCD use, similar to the recommendations in the European (Scientific Co-operation ) SCOOP-report on VLCD use (Supplementary Table 1) . 16 VLCD participants needed to sign a form, where they had been informed that VLCD use carries an increased risk of the adverse events listed in the SCOOP-report on VLCD use. 16 Weight loss phase (0-3 months). VLCD: Liquid-based formula diet of 500 kcal per day for 6-10 weeks (Itrim, Stockholm, Sweden; 125 kcal per sachet, 4 sachets per day, each sachet contained 13 g protein, 15 g carbohydrates, 2 g fat and 3 g fiber; approved as sole source VLCD by the Swedish National Food Agency), followed by a 2-week gradual introduction of normal food. Early introduction of normal food (6 as opposed to the full 10 weeks) occurred when the participant was either satisfied with the achieved weight loss or had reached a body mass index (BMI) o25.0 kg m À 2 . LCD: consisting of two calorie-restricted normal food meals and two formula diet meal replacement sachets (á 125 kcal), providing a total caloric intake of B1200-1500 kcal per day depending on body size and exercise levels. The normal food consisted of restricted portion sizes with a low overall energy density, high in protein, and with a low-glycemic index. 6 Weight maintenance phase (3-12 months). After the weight loss phase, the two groups entered the same 9-month weight maintenance program that included an exercise program (circuit training, with a mix of aerobic 
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min, physically active transport to and from work and using a Yamax SW-200 pedometer to encourage walking), dietary advice, selfmonitoring and behavioral changes. Dietary advice included the use of restricted portion sizes, and eating a diet rich in protein and with a lowglycemic index, with a low overall energy density. 6 
Data collection
Participant data. Anthropometric data were collected by companytrained health coaches at baseline, 3, 6 and 12 months, and recorded into the database of the commercial company. Body weight was measured in a nonfasting state with the Tanita TBF-300 bioelectrical impedance monitor (Tanita Corporation, Tokyo, Japan). Waist circumference was measured midway between the iliac crest and the lower rib cage (exhaled) with a measuring tape and was classified as normal (o80 cm for women/o94 cm for men), increased risk (80-87/94-101 cm) and high risk (X88/102 cm). 17 Height (without shoes) was measured by a wall-mounted stadiometer. World Health Organization BMI criteria (kg m À 2 ) were used to classify participants as underweight (o18.5), normal weight (18.5-24.9), overweight (25.0-29.9) and obese class I/II/III (30.0-34.9/35.0-39.9/X40). 18 Register data. Data on gallstones requiring hospital care, cholecystectomy, mortality and comorbidity were retrieved from National registers via register linkage. In Sweden, all the residents have a 10-digit personal identification number recorded in the medical files and nationwide health and census registers, enabling deterministic linkage.
History of gallstones, comorbidity and drug use. Data on the history of gallstones requiring hospital care during the 5 years before program were collected from the National Patient Register, which contains nationwide data on inpatient and nonprimary outpatient care in Sweden. Cholecystectomy history was retrieved from the same source from 1987 and onward. Data on hospital visits for malignancies (International Classification of Diseases [ICD] version 10 codes C00-C97) and circulatory disease (I00-I99) were also collected.
Drug dispensation data were retrieved from the nationwide Prescribed Drug Register during the 6 months preceding program start for antidiabetic drugs (Anatomical Therapeutic Classification [ATC] classification system codes A10A and A10B), antihypertensive drugs (C02, C03, C07, C08, C09), lipid-lowering drugs (C10AA, C10AB, C10AC, C10AD, C10B, C10AX), antidepressants (N06A), the antiobesity drugs orlistat (A08AB01), sibutramine (A08AA10) and rimonabant (A08AA11) and ursodeoxycholic acid (A05A).
Outcome and follow-up data. The primary outcome was gallstones requiring hospital care (cholelithiasis, ICD10 code K80). Cholecystectomy (procedure codes JKA20/JKA21) and all-cause mortality were investigated as secondary outcomes. Participants were followed from program start until first event, death, program end or 31 December, 2009, whichever came first. Cholecystectomized patients were excluded in the analysis of cholecystectomy but included in the analysis of gallstones requiring hospital care, as gallstones still can form in the gall ducts.
Gallstone and cholecystectomy data were retrieved from the National Patient Register. 15 Mortality data were retrieved from the Causes of Death Register, which contains information on 499% of all deaths in Sweden. 19 Statistical analysis LCD participants were matched with replacement to VLCD participants 1:1 by age ( þ / À 1-year), sex, BMI category, waist circumference category and previous gallstones. Analyses included all matched patients and were analyzed by intention to treat.
Kaplan-Meier curves were constructed to illustrate the absolute risk. To compare the risk of gallstones and cholecystectomy between the programs, we used conditional Cox regression to estimate hazard ratios over the 1-year follow-up (conditioned on the matching factors and adjusted for factors with significant differences at baseline).
A sensitivity analysis was conducted restricting the study population to participants without gallstones requiring hospital care during the 5 years preceding program start. Mortality was not analyzed due to few cases (one death due to unknown cause occurred in the VLCD group after the weight loss phase).
An exploratory analysis, combining the two intervention groups, was also conducted using multivariable Cox regression to investigate factors potentially associated with gallstones requiring hospital care, or cholecystectomy, including age, sex, baseline BMI, history of gallstones and weight loss during the rapid weight loss phase (0-3 months).
Data were analyzed using SAS (version 9.3). All reported P-values are two-sided and P-values o0.05 were regarded as statistically significant.
RESULTS
After matching LCD participants (n ¼ 4588) with replacement to VLCD participants (n ¼ 3773) 1:1 by age, sex, BMI, waist circumference, and previous gallstones, 3320 participants remained in each group (Figure 1 ).
Baseline characteristics At baseline, the mean age was 46 years, mean BMI 33.4 kg m À 2 and 83% were women. Fifty-one percent of the participants were class I obese, 23% were class II obese, 8% were class III obese and 19% were overweight.
The two treatment groups were balanced regarding circulatory disease, malignancy history and the use of lipid-lowering drugs and antidepressants. There were fewer users in the VLCD than in the LCD group of antidiabetes drugs (1.8 versus 3.3%; mean difference, À 1.4%, 95% CI À 0.7 to À 2.2%; Po0.001) and antihypertensives (16.7% versus 19.4%; mean difference, À 2.7%, 95% CI À 0.8 to À 4.5%; P ¼ 0.005; Table 1 ). At baseline, 0.9% (n ¼ 58/6640) had a history of gallstones requiring hospital care, of which 74% (n ¼ 43/58) had been cholecystectomized (Table 1) .
Weight change Eighty-two percent of the VLCD group and 78% in the LCD group completed the 1-year program (odds ratio, 1.3, 95% CI 1.2-1.5; Po0.001). After the initial weight loss phase (0-3 months; baseline observation carried forward), weight loss was 12.7 versus 7.9 kg (adjusted mean difference, 4.6, 95% CI 4.4-4.9; Po0.001). After the entire 1-year program, weight loss was 11.1 versus 8.1 kg (adjusted mean difference, 2.8, 95% CI 2.4-3.1; Po0.001; Figure 2 ). Data for the unmatched population have been described elsewhere. 6 Risk of gallstones requiring hospital care During 6361 person-years of follow-up, 48 gallstones occurred in the VLCD group and 14 in the LCD group (152 versus 44 per 10 000 person-years; conditional hazard ratio, 3.4, 95% CI 1.8 À 6.3; Po0.001; Figure 3 ; Table 2 ). The risk difference was 108 per 10 000 person-years (95% CI 59-157; Po0.001), resulting in a number-needed-to-harm of 92 (95% CI 63-168; Po0.001). Adjusting the main analysis for weight loss during the first 3 months attenuated the hazard ratio, but the hazard ratio remained higher with VLCD than LCD (2.5, 95% CI 1.3-5.1; Po0.001).
Risk of cholecystectomy
Including only participants who did not undergo a cholecystectomy preceding program start (n ¼ 3159 in the VLCD group and 3159 in the LCD group), 38 cases of cholecystectomy were performed during 6067 person-years of follow-up, of which 29 were in the VLCD group and 9 in the LCD group (96 versus 30 per 10 000 person-years; conditional hazard ratio, 3.2, 95% CI 1.5-6.8; P ¼ 0.003; number-needed-to-harm, 151, 95% CI 94-377; Po0.001; Figure 3 ; Table 2 ). Adjustment for weight loss during the first 3 months attenuated the hazard ratio (2.2, 95% CI 0.9-5.2; P ¼ 0.08).
Sensitivity analysis
Excluding participants with gallstones requiring hospital care during the 5 years preceding program start (n ¼ 58) resulted in Risk of gallstones and cholecystectomy after VLCD or LCD K Johansson et al similar results for gallstones (46 versus 13 in the VLCD and LCD group, respectively; 147 versus 41 per 10 000 person-years; hazard ratio, 3.4, 95% CI 1.8-6.3; number-needed-to-harm, 94, 95% CI 65-173; Po0.001) and cholecystectomy (28 in the VLCD group compared with 9 in the LCD group; 93 versus 30 per 10 000 person-years; hazard ratio, 3.2, 95% CI 1.5-6.8; number-neededto-harm, 158, 95% CI 97-420; P ¼ 0.002).
Exploratory analysis: predictors of gallstones and cholecystectomy during follow-up In multivariable analysis, the risk of developing gallstones requiring hospital care was higher in women than in men, in younger than in older participants, in those with a higher baseline BMI, among those who lost the most weight and in those with a history of gallstones (irrespective of cholecystectomy status; Supplementary Table 2 ). For cholecystectomy, the same factors as for gallstones requiring care were associated with an increased risk for cholecystectomy (Supplementary Table 3 ). 
DISCUSSION
In our analysis of symptomatic gallstones requiring hospital care or cholecystectomy in participants using either VLCD or LCD for the first 3 months of a 1-year commercial weight loss program, we found the absolute risk of gallstones as well as cholecystectomy to be low but approximately three times higher in the VLCD than in the LCD group. After adjusting for weight loss during the first 3 months, the risk was attenuated but remained higher with VLCD than LCD, suggesting a direct effect of VLCD on gallstone disease. To the best of our knowledge, this is the largest controlled study of VLCD and of the risk of severe gallstone problems and the first large-scale safety analysis of a commercial program.
Previous research Previous studies have investigated the association between VLCD and ultrasonography-assessed gallstone formation, rather than the risk of gallstones as a serious adverse event requiring hospital care and/or cholecystectomy. The majority of these studies were conducted in the late 1980s and early 1990s using VLCDs containing low levels of fat (E1g per day). [10] [11] [12] [13] [14] In a review of these studies, 20 Everhart reported that 10-25% of VLCD participants developed gallstones, one-third of which were symptomatic. Limitations of these studies were the lack of control groups, small sample sizes and short follow-up (8-36 weeks). [10] [11] [12] [13] [14] Later studies included VLCDs containing higher fat content (12-30 g per day), [21] [22] [23] [24] two of which were randomized controlled trials. 21, 22 None developed systematic gallstones in the high-fat group in either of the studies, suggesting that an adequate fat intake reduces gallstone formation. The fat content of the VLCD in our study was 7-9g per day, consistent with the 7g per day recommendation given by the European SCOOP-report on VLCD use. 16 The higher risk with VLCD in our study suggests that fat content may need to be increased even further to reduce the risk to LCD levels.
Mechanisms
Increased risk for gallstone formation during VLCDs could be explained by inadequate fat content of the diet and/or the rapid weight loss associated with VLCDs. Rapid weight loss, either by VLCD or bariatric surgery, is a known risk factor for gallstone formation. 20 The two most commonly suggested mechanisms for gallstone formation are supersaturation of bile with cholesterol, leading to cholesterol crystallization and stone formation, and the insufficient gallbladder emptying due to impaired motility. 25 Rapid weight loss induced by VLCDs is believed to affect both the mechanisms: Supersaturation is believed to be caused by decreased bile salt levels and increased cholesterol levels, and impaired motility due to reduced gallbladder stimulation because of the low-fat content. 26, 27 However, as described previously, a fat intake of 7-10 g per day has been reported as a threshold for maintaining an efficient gallbladder emptying. 16, 26 The majority of the gallstones requiring hospital care occurred during the maintenance phase (37/48 in the VLCD group and 8/14 in the LCD group). This was also the case in a previous study of VLCD as a treatment for sleep apnea (3/3 gallstones reported during the maintenance phase). 28, 29 Clinical implications Increased risk of gallstone formation during and after VLCDinduced rapid weight loss is incorporated in clinical recommendations as an adverse event, advising physicians to inform patients about this risk, but the risk magnitude has been unclear. 7, 16, 20 Our findings indicate a small, absolute but substantially elevated relative risk of gallstones requiring hospital care and/or cholecystectomy when using VLCD instead of LCD.
Whether the benefits of the additional weight loss in the VLCD group are worth the extra risk for gallstones and cholecystectomy may depend on patients' disease and risk factor status, as well as their preferences. Supplementation with omega-3 fatty acids and/or the use of ursodeoxycholic acid during the rapid weight loss phase could possibly reduce gallstone formation. 26, 30 Strengths and limitations The strengths of the current study include the large sample of weight loss participants in a real-life setting, with a direct VLCD and LCD comparison. With the risk of symptomatic gallstones being low, statistical power may become an issue in smaller studies. Our large study made it possible to study the risk of symptomatic gallstones leading to hospitalization and/or cholecystectomy as a serious adverse event to VLCD. Further, the outcomes were prospectively reported and data were collected routinely on a nationwide level in the universally accessible Swedish health-care system, with virtually complete follow-up.
The main limitation was the nonrandomized design. Baseline differences in age, sex, BMI, waist circumference and gallstone history were handled by matching. Multivariable adjustment was used for handling remaining baseline imbalances. However, residual confounding may exist. The results appeared to be robust in our sensitivity analyses.
Second, participants had selected and paid for the treatment themselves, possibly limiting generalizability to the wider overweight and obese population. Finally, the National Patient Register contains data on inpatient and nonprimary outpatient visits for gallstones, not visits in primary care, or undetected asymptomatic gallstones. Our results may therefore not be generalizable to mild or asymptomatic gallstones. However, our primary outcomes were gallstones requiring hospital care and cholecystectomies. Gallstones Abbreviations: VLCD, very-low calorie diet; LCD, low-calorie diet. a Hazard ratios were estimated conditioned on age, sex, gallstone history, baseline BMI, waist circumference and additionally adjusted for drug-treated diabetes and use of antihypertensives for the last 6 months. The analysis of gallstones requiring hospital care was also conditioned on history of cholecystectomy. 
